Patients who have heart failure with preserved ejection fraction (HFpEF) and high blood pressure in the lungs (pulmonary hypertension) experienced significant improvements in blood pressure and vascular health after taking the drug sotatercept, according to a study presented at the American College of Cardiology’s Annual Scientific Session (ACC.26).
New drug sotatercept shows benefit in CpcPH-HFpEF patients
- Post author:admin
- Post published:March 29, 2026
- Post category:uncategorized